Drug · CHEMBL35
FUROSEMIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. FUROSEMIDE. Drugs and targets, record CHEMBL35. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL35
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Aluzine 20, Aluzine 40, Aluzine 500, Aquamed, Diuresal, Dryptal, Froop, Frumax, Frumil, Frusetic, Frusid, Frusol, Furoscix, Hydroled, Lasix, Lasix ret, Rusyde, Tenkofruse
- ChEMBL
- Other names
- Frusemide, Furoscix, Furosemida, Furosemidum, LB-502, Logirene, Marsemide, Mirfat, NSC-269420, Oedemex
- ChEMBL
- Open Targets' highest stage
- Approval, for 8 of its 38 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SLC12A1 | Solute carrier family 12 member 1 | Sodium-(potassium)-chloride cotransporter 2 inhibitor | INHIBITOR | https://conductscience.org/library/genes/6557 |
Source ChEMBL
Diseases38
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 38Source Open Targets
See all 38 diseasesTrials276
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03296813 | TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure | Phase 3 | 2,973 | 2025-10-16 | furosemide | Its name | ClinicalTrials.gov |
| NCT00535925 | Nephropathy In Type 2 Diabetes and Cardio-renal Events | Phase 4 | 850 | 2020-05-11 | furosemide | Its name | ClinicalTrials.gov |
| NCT03259620 | A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts | Phase 3 | 491 | 2023-09-14 | furosemide | Its name | ClinicalTrials.gov |
| NCT02971891 | A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts | Phase 3 | 484 | 2023-09-14 | furosemide | Its name | ClinicalTrials.gov |
| NCT03556761 | Furosemide for Accelerated Recovery of Blood Pressure Postpartum | Phase 2 | 384 | 2020-09-10 | furosemide | Its name | ClinicalTrials.gov |
| NCT00577135 | Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study) | Phase 3 | 308 | 2013-05-27 | furosemide | Its name | ClinicalTrials.gov |
| NCT01644331 | Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure | Phase 3 | 257 | 2017-04-27 | furosemide | Its name | ClinicalTrials.gov |
| NCT00608491 | Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study) | Phase 3 | 188 | 2013-06-24 | furosemide | Its name | ClinicalTrials.gov |
| NCT02351934 | Early Diuresis Following Colorectal Surgery | Phase 4 | 123 | 2017-06-27 | furosemide | Its name | ClinicalTrials.gov |
| NCT01275729 | The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury | 96 | 2023-07-07 | furosemide | Its name | ClinicalTrials.gov |
1 to 10 of 276
See all 276 trialsComparisons in its trials133
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Torsemide vs Furosemide: All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death) | 149 of 1,431 | 157 of 1,428 | 2,859 | NCT03296813 | Trial comparisons |
| Torsemide vs Furosemide: All-cause Mortality, as Measured by Follow-up Phone Call or NDI | 373 of 1,431 | 374 of 1,428 | 2,859 | NCT03296813 | Trial comparisons |
| Torsemide vs Furosemide: All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death) | 677 of 1,431 | 704 of 1,428 | 2,859 | NCT03296813 | Trial comparisons |
| Torsemide vs Furosemide: deaths from any cause | 373 of 1,431 | 374 of 1,428 | 2,859 | NCT03296813 | Trial comparisons |
| CLS006 vs CLS006 Vehicle: deaths from any cause | 1 of 245 | 1 of 246 | 491 | NCT03259620 | Trial comparisons |
| CLS006 vs CLS006 Vehicle: serious adverse events | 3 of 245 | 3 of 246 | 491 | NCT03259620 | Trial comparisons |
| CLS006 (Furosemide) vs Vehicle: deaths from any cause | 0 of 246 | 0 of 238 | 484 | NCT02971891 | Trial comparisons |
| CLS006 (Furosemide) vs Vehicle: serious adverse events | 0 of 246 | 0 of 238 | 484 | NCT02971891 | Trial comparisons |
| Conventional Therapy vs Intensified Therapy: Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs) | 146 of 188 | 116 of 207 | 395 | NCT00535925 | Trial comparisons |
| Conventional Therapy vs Intensified Therapy: deaths from any cause | 103 of 188 | 86 of 207 | 395 | NCT00535925 | Trial comparisons |
1 to 10 of 133
See all 133 comparisons in its trialsPapers from its trials223
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL35
GET https://conductscience.org/api/drugs/v1/CHEMBL35/diseases?page=2